会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明申请
    • NOVEL CYCLIC UREA DERIVATIVES, PREPARATION THEREOF AND PHARMACEUTICAL USE THEREOF AS KINASE INHIBITORS
    • 新型环状尿素衍生物及其制备方法和作为激酶抑制剂的药物用途
    • WO2006010641A3
    • 2006-10-26
    • PCT/EP2005008720
    • 2005-07-25
    • AVENTIS PHARMA SASTROBEL HARTMUTRUF SVENLESUISSE DOMINIQUENEMECEK CONCEPTIONEL-AHMAD YOUSSEFGUESSREGEN STEFANLEBRUN ANNERITTER KURTBENARD DIDIERHITTINGER AUGUSTINBOUCHARD HERVE
    • STROBEL HARTMUTRUF SVENLESUISSE DOMINIQUENEMECEK CONCEPTIONEL-AHMAD YOUSSEFGUESSREGEN STEFANLEBRUN ANNERITTER KURTBENARD DIDIERHITTINGER AUGUSTINBOUCHARD HERVE
    • C07D401/06A61K31/4166C07D401/14
    • C07D403/04
    • The invention relates to products of formula (I): in which p = 0, 1 and 2; A = aryl, heteroaryl, carbocycle or heterocycle; X = single bond; -N(R6)-; -NH-alk-; alkylene; -O-; -C(O)-; -S(O)n-; -N(R6)-C(O)-; -NH-CO-alk-, -N(R6)-C(O)-N(R6')-; -N(R6)-C(S)-N(R6')-; -N(R6)-C(O)O-; -N(R6)-SO2-; -N(R6)-SO2-N(R6')-; -C(O)-N(R6)-; -SO2-NR6-; and -C(O)O-; L1 = single bond, alkylene, alkenylene, alkynylene, cycloalkylene, phenylene, heteroarylene; all optionally substituted; R1 = hydrogen, alkyl, alkenyl, alkynyl or cycloalkyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl; -SO2R9, -C(O)R9; -C(O)OR9,-C(O)NR10R11, -C(S)NR10R11,-SO2NR10R11; R2 = hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, either R1 and R2 with N, or NR1R2 with L1 may form a saturated or unsaturated heterocycle possibly containing O, N, S; R3 = hydrogen; halogen; alkyl, alkenyl, alkynyl, cycloalkyl, alkoxy, alkylenedioxy, heterocycle, aryl and heteroaryl, all optionally substituted; S(O)n-alkyl; amino, alkylamino, dialkylamino, with dialkylamino optionally forming with N a cycle, all optionally substituted; R4, R4' and R4''= hydrogen, halogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, oxo; with two from among R4, R4' and R4'' possibly forming with C a ring possibly containing O, N or S; L2 = single bond, alkylene, alkenylene, alkynylene, cycloalkylene, -O-, -NR17-, -C(O)-, SO2; Y = N-heterocycle possibly containing O, N or S; R5 = hydrogen, halogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl; all these radicals being optionally substituted, these products being in all the isomeric forms and the salts, as medicinal products.
    • 本发明涉及式(I)的产物:其中p = 0,1和2; A =芳基,杂芳基,碳环或杂环; X =单键; -N(R 6) - ; -NH-烷 - ; 亚; -O-; -C(O) - ; -儿子-; -N(R 6)-C(O) - ; -NH-CO-alk-,-N(R 6)-C(O)-N(R 6') - ; -N(R6)-C(S)-N(R6' ) - ; -N(R 6)-C(O)O-; -N(R 6)-SO 2 - ; -N(R6)-SO2-N(R6' ) - ; -C(O)-N(R6) - ; -SO 2 NR 6 - ; 和-C(O)O-; L1 =单键,亚烷基,亚烯基,亚炔基,亚环烷基,亚苯基,亚杂芳基; 全部任选被取代; R1 =氢,烷基,烯基,炔基或环烷基,芳基,杂芳基,芳基烷基,杂芳基烷基; -SO 2 R 9,-C(O)R 9; -C(O)OR 9,-C(O)NR 10 R 11,-C(S)NR 10 R 11,-SO 2 NR 10 R 11; R 2 =氢,烷基,烯基,炔基,环烷基,R 1和R 2与N或NR 1 R 2与L 1可以形成可能含有O,N,S的饱和或不饱和杂环; R3 =氢; 卤素; 烷基,烯基,炔基,环烷基,烷氧基,亚烷基二氧基,杂环,芳基和杂芳基,全部任选被取代; S(O)n-烷基; 氨基,烷基氨基,二烷基氨基,任选与N环形成的二烷基氨基,全部任选被取代; R4,R4'和R4“=氢,卤素,烷基,烯基,炔基,环烷基,芳基,杂芳基,氧代; 其中R4,R4'和R4“中的两个可能与C形成可能含有O,N或S的环; L2 =单键,亚烷基,亚烯基,亚炔基,亚环烷基,-O - , - NR17-,-C(O) - ,SO2; Y =可能含有O,N或S的N-杂环; R5 =氢,卤素,烷基,烯基,炔基,环烷基,芳基,芳基烷基,杂芳基,杂芳基烷基; 所有这些基团任选地被取代,这些产物以所有异构形式和盐作为医药产品。
    • 3. 发明申请
    • FLUORENE DERIVATIVES, COMPOSITION CONTAINING SAID DERIVATIVES AND THE USE THEREOF
    • 氟衍生物,含有该衍生物的组合物及其用途
    • WO2006123061A3
    • 2007-01-11
    • PCT/FR2006001137
    • 2006-05-19
    • AVENTIS PHARMA SAMAILLIET PATRICKBERTIN LUCGUYON THIERRYTHOMPSON FABIENNERUXER JEAN-MARIEPILORGE FABIENNEBENARD DIDIERMINOUX HERVECARREZ CHANTALGOULAOUIC HELENE
    • MAILLIET PATRICKBERTIN LUCGUYON THIERRYTHOMPSON FABIENNERUXER JEAN-MARIEPILORGE FABIENNEBENARD DIDIERMINOUX HERVECARREZ CHANTALGOULAOUIC HELENE
    • C07D471/04
    • C07D471/04C07D401/12
    • The invention relates to novel products of formula (1), wherein A1, A2, A3 and A4 are CRa or N, R1 and R1' are such that one represents H, Hal, C1C3-alkyl, C1C3-alkoxy, alkyl-OH, CF3, cyano, carboxy or carboxamido and the other represents Hal; CF3 ; OH ; SH; nitro; amino ; NH-OH ; NH-CO-H ; NH-CO-OH, NH-CO-O alkyl , NH-CO-NH2 ; carboxy ; CN ; CO-NH2 ; X-(CH2)m-alkyl; X-(CH2)m-cycloalkyl ; X-(CH2)m-heterocycloalkyl ; X-(CH2)m-aryl or X-(CH2)m-heteroaryl with X = simple bond, CH2, CH=CH, CH2-O, CH2-NH, CH2-C(O), CH2-C(O)-O, CH2-C(O)-NH, CH2-NH-(CO), CH2-NH-S(O), CH2-NH-S(O)2, O, S, NH, O-C(O), C(O)-NH, -NH-C(O), -NH-C(O)-C(O)-, -NH-C(O)-NH-, ; NH-CS, NH-S(O) or NH-S(O)2 ; m = 0, 1 or 2, or R1 and R'1 form with C to which they are bound either a radical =O ; =S ; =N-OH ; =N-NH2 ; =N-NH-CO-NH2, =CH-OH ; =Y1-(CH2)m-aryl or =Y1-(CH2)m heteroaryl, wherein Y1 represents CH, CH-CO-, CH-CO-NH, N, N-O or N-NH-, where m = 0, 1 or 2, or a cycle, R2 et R'2 represent H, halogen, CF3, nitro, cyano, alkyl, hydroxy, mercapto, amino, alkylamino, dialkylamino, alkoxy, alkylthio, free or esterified carboxy, carboxamide, CO-NH(alkyl) et CO N(alkyl)2, p= 1 à 3 et p'= 1 à 4; Ra represents H ; halogen ; CF3 ; hydroxy ; mercapto ; nitro ; amino ; NH-OH ; NH-CO-H ; NH-CO-NH2 ; carboxy ; CN ; CO-NH2 ; Y-(CH2)n-alkyl ; Y-(CH2)n-cycloalkyl, Y-(CH2)n-heterocycloalkyl, Y-(CH2)n-aryl or Y-(CH2)n-heteroaryl, with Y = O, S, NH, O-C(O), C(O)-NH, NH-C(O), NH-S(O) or NH-S(O)2, with n = 0, 1, 2 or 3, wherein all alkyl, alkoxy, alkylthio, cycloalkyl, heterocycloalkyl, aryl and heteroaryl radicals are optionally substituted and all products in any forms are tautomers and isomers and the salts, which are used in the form of drugs.
    • 本发明涉及式(1)的新产物,其中A 1,A 2,A 3和A 4为CR a或N,R 1和R 1'表示H,Hal,C 1 -C 3 - 烷基,C 1 -C 3 - 烷氧基,烷基-OH, CF 3,氰基,羧基或甲酰氨基,另一个表示Hal; CF3; OH; SH; 硝基; 氨基; NH-OH; NH-CO-H; NH-CO-OH,NH-CO-O烷基,NH-CO-NH2; 羧基 CN; CO-NH2; X-(CH 2)M-烷基; X-(CH 2)m - 环烷基; X-(CH 2)m - 杂环烷基; X =简单键,CH2,CH = CH,CH2-O,CH2-NH,CH2-C(O),CH2-C(O)的X-(CH2)m-芳基或X- -O,CH 2 -C(O)-NH,CH 2 -NH-(CO),CH 2 -NH-S(O),CH 2 -NH-S(O)2,O,S,NH,OC(O) C(O)-NH,-NH-C(O),-NH-C(O)-C(O) - , - NH-C(O) NH-CS,NH-S(O)或NH-S(O)2; m = 0,1或2,或者R1和R'1与它们所结合的C形成基团= O; = S; = N-OH; = N-NH 2; = N-NH-CO-NH 2 = CH-OH; = Y1-(CH2)m-芳基或= Y1-(CH2)m杂芳基,其中Y1表示CH,CH-CO-,CH-CO-NH,N,NO或N-NH-,其中m = R 2和R 2代表H,卤素,CF 3,硝基,氰基,烷基,羟基,巯基,氨基,烷基氨基,二烷基氨基,烷氧基,烷硫基,游离或酯化羧基,羧酰胺,CO-NH 烷基)和CO N(烷基)2,p = 1à3 et p'= 1à4; Ra表示H; 卤素 CF3; 羟基; 巯基 硝基; 氨基; NH-OH; NH-CO-H; NH-CO-NH2; 羧基 CN; CO-NH2; Y-(CH 2)n - 烷基; Y - (CH 2)n - 环烷基,Y-(CH 2)n - 杂环烷基,Y-(CH 2)n - 芳基或Y-(CH 2)n - 杂芳基,其中Y = O,S,NH,OC(O) C(O)-NH,NH-C(O),NH-S(O)或NH-S(O)2,其中n = 0,1,2或3,其中全部烷基,烷氧基,烷硫基,环烷基, 杂环烷基,芳基和杂芳基任选被取代,并且任何形式的所有产物都是以药物形式使用的互变异构体和异构体和盐。
    • 5. 发明申请
    • NOVEL CYCLIC UREA DERIVATIVES, PREPARATION METHOD THEREOF AND PHARMACEUTICAL USE OF SAME AS KINASE INHIBITORS
    • 新型循环尿素衍生物,其制备方法及其作为激酶抑制剂的药物应用
    • WO2004070050A2
    • 2004-08-19
    • PCT/FR2004000188
    • 2004-01-28
    • AVENTIS PHARMA SA
    • PATEK MARCELNAIR ANILHITTINGER AUGUSTINNEMECEK CONCEPTIONBOND DANIELHARLOW GREGBOUCHARD HERVEMAUGER JACQUESMALLERON JEAN-LUCPALERMO MARKAL-OBEIDI FAHADFAITG THOMASSTROBEL HARTMUTRUF SVENRITTER KURTEL-AHMAD YOUSSEFLESUISSE DOMINIQUEBENARD DIDIER
    • A61P3/00A61P7/02A61P11/06A61P17/06A61P19/02A61P25/00A61P35/00C07D401/06C07D401/14C12Q
    • C07D401/06C07D401/14
    • The invention relates to novel products having formula (I), wherein: p denotes 0 to 2; R and R1 denote O or NH; R2 and R3 denote hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl and heteroaryl, or R2 and R3, together with the carbon atom to which they are bound, form a carbocyclic or heterocyclic radical, all of said radicals being optionally substituted; A1 denotes a single bond, alkyl, allyl and propynyl; Y and Y1 denote H, OCF3, S(O)nCF3, S(O)nAlk, SO2CHF2, SO2CF2CF3, -O-CF2-CHF2, -O-CHF2, -O-CH2-CF3, SF5 and SO2NR5R6, whereby R5 and R6 are selected from among hydrogen, alkyl, alkenyl, cycloalkyl, cycloalkenyl, heterocycloalkyl, aryl and heteroaryl, which are optionally substituted, or R5 and R6, together with N to which they are bound, form a heterocyclic radical; A2 denotes Al, CO and SO2; B2 denotes a heterocyclic radical which is optionally substituted with one or more substituents which are selected from the values of Y2; Y2 denotes hydrogen, halogen, hydroxyl, cyano, alkyl, alkoxy, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, -O-alkenyl, -O-alkynyl, O-cycloalkyl, S(O)n-alkyl, -S(O)n-alkenyl, -S(O)n-alkynyl, S(O)n-cycloalkyl, -COOR13,-OCOR13, NR5R6, CONR5R6, S(O)n-NR5R6,-NR10-CO-R13, -NR10-SO2-R13, -NH-SO2-NR5R6, -NR10-CO-NR5R6, -NR10-CS-NR5R6, -NR10-COOR13, all of said radicals being optionally substituted; and n denotes an integer of between 0 and 2. The aforementioned products are in all the isomeric forms and the salts thereof for use as medicaments.
    • 本发明涉及具有式(I)的新产品,其中:p表示0至2; R和R1表示O或NH; R 2和R 3表示氢,烷基,烯基,炔基,环烷基,芳基和杂芳基,或者R 2和R 3与它们所连接的碳原子一起形成碳环或杂环基,所有基团都是任选被取代的; A1表示单键,烷基,烯丙基和丙炔基; Y和Y1表示H,OCF3,S(O)nCF3,S(O)nAlk,SO2CHF2,SO2CF2CF3,-O-CF2-CHF2,-O-CHF2,-O-CH2-CF3,SF5和SO2NR5R6, R 6选自任选取代的氢,烷基,烯基,环烷基,环烯基,杂环烷基,芳基和杂芳基,或R 5和R 6与它们所连接的N一起形成杂环基; A2表示Al,CO和SO2; B2表示任选被一个或多个选自Y2的取代基取代的杂环基; 环烷基,杂环烷基,芳基,杂芳基,-O-烯基,-O-炔基,O-环烷基,S(O)n - 烷基,-S(O)n - 烯基,-S(O)n - 炔基,S(O)n-环烷基,-COOR 13,-OCOR 13,NR 5 R 6,CONR 5 R 6,S(O)n -NR 5 R 6,-NR 10 -CO-R 13,-NR 10 -SO 2 - R13,-NH-SO2-NR5R6,-NR10-CO-NR5R6,-NR10-CS-NR5R6,-NR10-COOR13,所有所述基团任选被取代; 并且n表示0和2之间的整数。上述产物是全部异构形式及其盐,用作药物。